Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Area of Science:

• Neuroscience
• Immunology
• Oncology

Background:

• Brain tumors are difficult to treat solid tumors.
• Chimeric Antigen Receptor T (CAR-T) cell therapy shows promise for hematological malignancies but faces challenges in brain tumors.
• Neurotransmitters influence T-cell anti-tumor immunity, but research is limited to peripheral tumors.

Purpose of the Study:

• To highlight the importance of local brain neurotransmitters in CAR-T cell therapy for brain tumors.
• To propose engineering CAR-T cells considering both tumor antigens and the brain microenvironment.
• To advocate for integrating neurochemical profiling into CAR-T design for precision neuro-immunotherapy.

Main Methods:

• This is a perspective article, not an experimental study.
• It reviews current understanding of neurotransmitter modulation of T cells.
• It discusses the unique challenges of the brain microenvironment for CAR-T cell therapy.

Main Results:

• Neurotransmitter modulation of T cells differs in the brain compared to peripheral tumors.
• CAR-T cell engineering must account for brain-specific signaling and metabolic pressures.
• Tailoring CAR-T cells to the local neurochemical environment is crucial for efficacy.

Conclusions:

• Integrating brain regional neurochemical profiling into CAR-T design is strategically important.
• This approach can lead to precision neuro-immunotherapy for brain tumors.
• Treatment optimization is possible, especially for patients on neuromodulator drugs.